RecruitingPhase 2NCT04500665

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine


Sponsor

Brigham and Women's Hospital

Enrollment

20 participants

Start Date

Nov 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.


Eligibility

Min Age: 21 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether colchicine — an inexpensive anti-inflammatory medication often used for gout — can protect the heart in people with chronic kidney disease. People with kidney disease often develop a type of heart damage, and this study investigates whether reducing inflammation can help. **You may be eligible if...** - You are 21 to 80 years old - You have reduced kidney function (eGFR between 15 and 75) - Your urine test shows elevated protein levels (albumin-to-creatinine ratio above 30) - You are on maximum tolerated doses of standard kidney-protective medications (ACE inhibitor or ARB) if applicable **You may NOT be eligible if...** - You are already on dialysis or have had a kidney transplant - You have active liver disease - You have a history of colchicine intolerance - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGColchicine

Colchicine

DRUGPlacebo

Placebo


Locations(1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04500665


Related Trials